ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Compugen Expands Collaboration with Bristol Myers Squibb in COM701, Opdivo Study
February 26, 2021Compugen announced the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study ... -
Compugen Announces Triple Combination Study to Evaluate COM701, Opdivo, TIGIT Inhibitor
March 09, 2020Compugen announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an investigational anti-PVRIG antibody ... -
Compugen Announces First Patient Dosed with COM701
September 10, 2018Compugen announced the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. -
FDA demand puts Compugen’s solid tumor checkpoint trial on ice
April 28, 2018The FDA has temporarily blocked Compugen’s plans to start a phase 1 trial of PVRIG-targeting cancer drug COM701.
Pharma Sources Insight January 2025
